Synaffix partners with SOTIO Biotech in deal worth up to $740m
SOTIO will gain access to Synaffix’s three ADC technologies
Read More
Tag: antibody-drug conjugate
Iksuda Therapeutics raises $47m to progress ADC pipeline
Iksuda will use the funds to support the progression of IKS03 into first-in-human Phase I clinical trials
Read More
AZ/Daiichi Sankyo’s antibody drug conjugates prove promising in early trials
Datopotamab deruxtecan and Enhertu were evaluated in non-small cell lung cancer patients
Read More
Iksuda Therapeutics exercises licensing rights from University of Goettingen
Agreement covers protein-alkylating, tumour-activated pro-drug payload series for ADC development
Read More
AstraZeneca and Daiichi sign $6.9bn cancer drug deal
The collaboration is aligned with AstraZeneca’s science-led strategy in oncology.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
